257 related articles for article (PubMed ID: 25573533)
1. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Bendell J; O'Reilly EM; Middleton MR; Chau I; Hochster H; Fielding A; Burke W; Burris H
Ann Oncol; 2015 Apr; 26(4):804-811. PubMed ID: 25573533
[TBL] [Abstract][Full Text] [Related]
2. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
Plummer R; Madi A; Jeffels M; Richly H; Nokay B; Rubin S; Ball HA; Weller S; Botbyl J; Gibson DM; Scheulen ME
Cancer Chemother Pharmacol; 2013 Jan; 71(1):93-101. PubMed ID: 23064954
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
Siegel-Lakhai WS; Crul M; Zhang S; Sparidans RW; Pluim D; Howes A; Solanki B; Beijnen JH; Schellens JH
Br J Cancer; 2005 Nov; 93(11):1222-9. PubMed ID: 16251868
[TBL] [Abstract][Full Text] [Related]
4. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
de Haan R; van Werkhoven E; van den Heuvel MM; Peulen HMU; Sonke GS; Elkhuizen P; van den Brekel MWM; Tesselaar MET; Vens C; Schellens JHM; van Triest B; Verheij M
BMC Cancer; 2019 Sep; 19(1):901. PubMed ID: 31500595
[TBL] [Abstract][Full Text] [Related]
5. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M; Cleary JM; Shyr Y; Chao J; Uboha N; Cho M; Shields A; Pant S; Goff L; Spencer K; Kim E; Stein S; Kortmansky JS; Canosa S; Sklar J; Swisher EM; Radke M; Ivy P; Boerner S; Durecki DE; Hsu CY; LoRusso P; Lacy J
Br J Cancer; 2024 Feb; 130(3):476-482. PubMed ID: 38135713
[TBL] [Abstract][Full Text] [Related]
6. A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Jones R; Plummer R; Moreno V; Carter L; Roda D; Garralda E; Kristeleit R; Sarker D; Arkenau T; Roxburgh P; Walter HS; Blagden S; Anthoney A; Klencke BJ; Kowalski MM; Banerji U
Clin Cancer Res; 2023 Jan; 29(2):331-340. PubMed ID: 36378548
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors.
Seetharam M; Norman A; Allred J; Kong J; Opyrchal M; Ma WW; Lou Y; Dy GK; Mahipal A; Weroha J; Wahner-Hendrickson A; Reid JM; Adjei AA
Res Sq; 2024 Apr; ():. PubMed ID: 38746220
[TBL] [Abstract][Full Text] [Related]
8. Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
Meric-Bernstam F; Sweis RF; Hodi FS; Messersmith WA; Andtbacka RHI; Ingham M; Lewis N; Chen X; Pelletier M; Chen X; Wu J; Dubensky TW; McWhirter SM; Müller T; Nair N; Luke JJ
Clin Cancer Res; 2023 Jun; 29(12):2336. PubMed ID: 37309603
[No Abstract] [Full Text] [Related]
9. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.
Yarchoan M; Myzak MC; Johnson BA; De Jesus-Acosta A; Le DT; Jaffee EM; Azad NS; Donehower RC; Zheng L; Oberstein PE; Fine RL; Laheru DA; Goggins M
Oncotarget; 2017 Jul; 8(27):44073-44081. PubMed ID: 28454122
[TBL] [Abstract][Full Text] [Related]
10. Olaparib effective in four advanced cancers.
Cancer Discov; 2015 Jan; 5(1):OF3. PubMed ID: 25583815
[TBL] [Abstract][Full Text] [Related]
11. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
[TBL] [Abstract][Full Text] [Related]
12. Olaparib: first global approval.
Deeks ED
Drugs; 2015 Feb; 75(2):231-40. PubMed ID: 25616434
[TBL] [Abstract][Full Text] [Related]
13. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
Kummar S; Oza AM; Fleming GF; Sullivan DM; Gandara DR; Naughton MJ; Villalona-Calero MA; Morgan RJ; Szabo PM; Youn A; Chen AP; Ji J; Allen DE; Lih CJ; Mehaffey MG; Walsh WD; McGregor PM; Steinberg SM; Williams PM; Kinders RJ; Conley BA; Simon RM; Doroshow JH
Clin Cancer Res; 2015 Apr; 21(7):1574-82. PubMed ID: 25589624
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitors: A new era of targeted therapy.
Tangutoori S; Baldwin P; Sridhar S
Maturitas; 2015 May; 81(1):5-9. PubMed ID: 25708226
[TBL] [Abstract][Full Text] [Related]
15. An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Mateo J; Moreno V; Gupta A; Kaye SB; Dean E; Middleton MR; Friedlander M; Gourley C; Plummer R; Rustin G; Sessa C; Leunen K; Ledermann J; Swaisland H; Fielding A; Bannister W; Nicum S; Molife LR
Target Oncol; 2016 Jun; 11(3):401-15. PubMed ID: 27169564
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
Leichman L; Groshen S; O'Neil BH; Messersmith W; Berlin J; Chan E; Leichman CG; Cohen SJ; Cohen D; Lenz HJ; Gold P; Boman B; Fielding A; Locker G; Cason RC; Hamilton SR; Hochster HS
Oncologist; 2016 Feb; 21(2):172-7. PubMed ID: 26786262
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B
Gynecol Oncol; 2016 Feb; 140(2):199-203. PubMed ID: 26723501
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
van der Noll R; Marchetti S; Steeghs N; Beijnen JH; Mergui-Roelvink MW; Harms E; Rehorst H; Sonke GS; Schellens JH
Br J Cancer; 2015 Jul; 113(3):396-402. PubMed ID: 26180927
[TBL] [Abstract][Full Text] [Related]
19. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
